AbbVie, Merck & Co., Inc., Insmed, Eli Lilly and Company, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture and market medications and related healthcare products. Investors in these stocks gain exposure to the industry’s drug development pipeline, patent‐protected revenue streams and regulatory approval process. Their performance is often driven by clinical trial results, government approvals and competitive dynamics within global healthcare markets. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
AbbVie stock traded down $4.90 during trading hours on Friday, hitting $181.89. The stock had a trading volume of 29,262,557 shares, compared to its average volume of 6,249,513. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64. The stock has a market capitalization of $321.29 billion, a price-to-earnings ratio of 77.40, a PEG ratio of 1.21 and a beta of 0.50. AbbVie has a 1-year low of $163.52 and a 1-year high of $218.66. The stock's fifty day moving average is $186.21 and its two-hundred day moving average is $188.01.
Read Our Latest Research Report on ABBV
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Shares of MRK traded up $0.10 on Friday, hitting $78.93. 60,171,714 shares of the stock traded hands, compared to its average volume of 13,155,543. The stock's 50 day moving average is $79.06 and its two-hundred day moving average is $87.64. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $129.93. The firm has a market capitalization of $198.20 billion, a P/E ratio of 11.49, a P/E/G ratio of 0.82 and a beta of 0.38. The company has a quick ratio of 1.16, a current ratio of 1.41 and a debt-to-equity ratio of 0.69.
Read Our Latest Research Report on MRK
Insmed (INSM)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Shares of Insmed stock traded down $2.25 during trading hours on Friday, reaching $99.49. The stock had a trading volume of 34,467,302 shares, compared to its average volume of 2,299,115. The firm has a market capitalization of $18.87 billion, a price-to-earnings ratio of -16.72 and a beta of 0.80. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. Insmed has a 1 year low of $60.40 and a 1 year high of $106.83. The firm has a 50 day simple moving average of $78.01 and a two-hundred day simple moving average of $75.55.
Read Our Latest Research Report on INSM
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
NYSE LLY traded down $18.94 during mid-day trading on Friday, reaching $776.18. 4,109,419 shares of the company's stock traded hands, compared to its average volume of 3,683,590. The company has a market cap of $735.61 billion, a price-to-earnings ratio of 63.16, a P/E/G ratio of 1.13 and a beta of 0.40. The company has a fifty day simple moving average of $780.19 and a 200-day simple moving average of $799.96. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.
Read Our Latest Research Report on LLY
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Shares of GILD traded up $3.05 during mid-day trading on Friday, hitting $110.67. The stock had a trading volume of 19,541,254 shares, compared to its average volume of 7,682,147. Gilead Sciences has a fifty-two week low of $66.01 and a fifty-two week high of $119.96. The company has a market cap of $137.67 billion, a PE ratio of 23.30, a PEG ratio of 0.72 and a beta of 0.29. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The company's fifty day simple moving average is $106.39 and its two-hundred day simple moving average is $103.35.
Read Our Latest Research Report on GILD
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
